By utilising augmented intelligence early, small and mid-sized companies can maximise their innovation potential, minimise ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

Three behavioural phenomena are particularly consequential in screening and prevention research: ...

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...